MedTrace Logo

Use and Costs of P2Y12 Inhibitors After Acute Myocardial Infarction

NCT07610577 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 377753

Last updated 2026-05-28

No results posted yet for this study

Summary

This study aims to describe temporal trends in the use and costs of clopidogrel, ticagrelor, and prasugrel in Germany and the United States.

Conditions

  • Acute Myocardial Infarction (AMI)

Interventions

DRUG

Clopidogrel

Initiation of clopidogrel in healthcare claims is used as the exposure.

DRUG

Prasugrel

Initiation of prasugrel in healthcare claims is used as the exposure.

DRUG

Ticagrelor

Initiation of ticagrelor in healthcare claims is used as the exposure.

Sponsors & Collaborators

  • Brigham and Women's Hospital

    lead OTHER

Principal Investigators

  • Nils Kruger, MD · Brigham and Women's Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-01
Primary Completion
2026-05-31
Completion
2026-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07610577 on ClinicalTrials.gov